Clearly Hormonal

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question.

Endocrinologist Dr. Komal Patil-Sisodia defines peptides as short amino-acid chains (with examples like insulin) and notes that any package or claim stating “contains peptides” is meaningless without knowing which peptide, how it was tested, and what it's proven to do.

She outlines the FDA approval pathway from preclinical work through Phase 1–3 trials and FDA review, then lists the FDA-approved peptides she prescribes for metabolic health (insulin analogs, GLP-1/GIP agents, glucagon, pramlintide), osteoporosis and calcium disorders (teriparatide, abaloparatide, palopegteriparatide, calcitonin), and reproductive/pituitary conditions (GnRH agonists, somatostatin analogs, vasopressin/desmopressin, cosyntropin, setmelanotide, bremelanotide).

She contrasts these with trending “gray market” peptides (e.g., BPC-157, TB-500, GHK-Cu), noting most lack published peer-reviewed randomized human trials and are often sold as “research chemicals” without purity oversight. Her key filter: ask what high-quality human evidence supports a claim — emphasizing informed choices, doctor-guided decisions, and evidence over hype.

In This Episode

• What a peptide actually is — and why the word alone doesn't mean anything
• The FDA's Phase 1–3 approval pathway, explained in plain language
• The full list of FDA-approved peptides Dr. Patil-Sisodia prescribes, organized by condition
• Why trending “gray market” peptides like BPC-157, TB-500, and GHK-Cu haven't cleared that same evidence bar
• The backlash from a recent social post — and what it revealed about asking for sources
• The one question to ask before trying any new treatment

Timestamps

00:00 | Welcome to Clearly Hormonal
01:03 | Peptides Everywhere Now
01:51 | Peptides Explained Simply
02:47 | How FDA Approval Works
05:13 | Peptides I Prescribe
08:42 | Social Media Peptide Hype
10:43 | My Viral Post Backlash
12:53 | Spotting Real Evidence
13:46 | Final Takeaways and Wrap

Connect

• Practice: eastsidemm.com
• Instagram & TikTok: @drpatilsisodia

Thanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question.

Dr. Komal Patil-Sisodia explains that headlines claiming “FDA approves peptides” are misleading: an FDA advisory committee narrowly voted to recommend adding six peptides (BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax) to a compounding list, a step that is not FDA approval and still faces a formal FDA process. She notes FDA scientists opposed adding all six and that some voting members sell these peptides.

Reviewing the evidence, she explains that BPC-157 has only three small, weak human studies; TB-500 has zero human trials for the injury uses it's marketed for (while full thymosin beta-4 has some real human data); KPV has no human studies at all; MOTS-c has an unpublished Phase 1b trial and only observational, exercise-related human data; Epitalon lacks Western peer-reviewed human trials; and Semax is approved in Russia but with limited-quality stroke data.

She emphasizes that all six are synthetic despite being marketed as "natural," that marketing to midlife women is running well ahead of the evidence, that contamination and mislabeled dosing have been documented in online peptide products, that compounded drugs bypass typical FDA review, and that proven options already exist for symptoms like hot flashes, bone loss, and metabolic changes.

Time Stamps:

00:00  Welcome to Clearly Hormonal

01:03  The FDA Vote Explained

03:09  BPC-157 Evidence Check

04:31  TB-500 vs. Thymosin Beta-4

06:01  KPV and Animal Data Limits

07:25  MOTS-c, Epitalon, Semax

11:32  Midlife Marketing Reality

13:37  What the List Means

14:23  Safety and Contamination Risks

16:06  Bottom Line and Next Steps

17:31  Wrap Up and Where to Follow

Resources & Mentions

• Follow Dr. Patil-Sisodia on Instagram and TikTok: @drpatilsisodia
• JAMA: “Under FDA, Unapproved Peptides Likely to Become More Widely Available” (Rita Rubin, MA, 2026)
• ABC News: “FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next?” (July 24, 2026)
• Talanta (2018): impurity analysis of falsified peptide drugs seized from online pharmacies
• Expert Opinion on Drug Safety (2026): FAERS pharmacovigilance study on compounded GLP-1 receptor agonists
• Journal of Cellular and Molecular Medicine (2021): Phase I dose-escalation trial of recombinant human thymosin beta-4
• Zhurnal Nevrologii I Psikhiatrii (2018): Semax post-stroke rehabilitation study

Thanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question.

Type 1 diabetes isn't just a childhood disease, and it isn't caused by sugar, weight, or lifestyle. In this episode, Dr. Komal Patil-Sisodia breaks down why type 1 diabetes is so often missed in adults, especially in people mislabeled as type 2, and introduces LADA (latent autoimmune diabetes in adults), a slow-moving form of type 1 that may account for up to a quarter of adult diagnoses. She walks through the clues that should prompt testing, the two blood tests that can change a diagnosis, and how perimenopause and menopause complicate blood sugar control for women living with type 1. The episode also covers pregnancy planning, the real (and often overstated) genetic risk to children, the underappreciated heart disease risk in women with type 1, and why needing insulin is never a sign of failure.

In This Episode

• Why type 1 diabetes has nothing to do with sugar, weight, or lifestyle
• How adult-onset type 1 gets misdiagnosed as type 2, and why
• LADA (type 1.5): what it is and why it hides in plain sight
• The clues that should prompt a GAD antibody and C-peptide test
• How perimenopause and menopause make blood sugar harder to control
• Pregnancy with type 1 diabetes: what's actually true
• The real genetic risk to children (it's lower than you think)
• Why heart disease risk is elevated and underdiscussed in women with type 1
• Why insulin is not a “last resort” and never a sign you did something wrong
• The technology (CGMs and automated insulin delivery) changing type 1 care

Timestamps:

00:00   Why Type 1 Gets Missed

00:30   A Misdiagnosed Patient Story

02:52   Myth: Sugar Causes Type 1

05:31   Myth: Only Kids Get It

06:29   Adult Onset and the Honeymoon Period

08:41   LADA (Type 1.5) Explained

10:13   Perimenopause Makes It Harder

11:53   When to Test for Type 1

14:34   Pregnancy Myths and Facts

16:41   Heart Risk in Women

18:24   Insulin Shame and Stigma

20:44   Tech That Changed Diabetes Care

22:01   Perimenopause Management Tips

22:49   Key Takeaways and Next Steps

25:14   Final Thoughts and Share

Resources Mentioned:

• GAD antibody test (glutamic acid decarboxylase antibody): the key immune marker for LADA
• C-peptide test: measures how much insulin your body is still producing on its own
• Continuous glucose monitors (CGMs) and automated insulin delivery systems
• Maternal-fetal medicine (perinatology) preconception counseling for planned pregnancies

Disclaimer: 

This podcast is for education, not personalized medical advice. Please discuss anything that resonates with your own healthcare team.

Thanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question.

Type 2 Diabetes Isn't a Moral Failing: Genetics, Hormones, Stigma, and the Truth About Insulin

If you've ever been told — or told yourself — that your type 2 diabetes is something you caused and something you could fix if you just tried a little harder, this episode is for you.

Dr. Komal Patil-Sisodia spends 17 years of clinical experience (and personal family history) dismantling one of the most damaging narratives in medicine: that type 2 diabetes is a lifestyle disease you can will your way out of. In reality, it's a complex, progressive metabolic condition shaped by genetics, hormones, sleep, stress, and — for women specifically — perimenopause and menopause.

This episode covers the real biology behind insulin resistance and beta-cell decline, why stigma is measurably making patient outcomes worse, why so many people misunderstand what insulin actually does, and why "remission" — not "reversal" — is the accurate, honest term for what's possible.

In this episode:

• 00:00 — Welcome and Mission Introduction to Clearly Hormonal and why this particular episode is personal.
• 01:00 — Diabetes Myths and Stigma The core myth — that diabetes is caused by bad choices and reversible through willpower — and the data on how stigma affects A1C, depression, and self-care engagement.
• 03:18 — A Patient Story: A Midlife Shift A composite patient story of someone doing everything "right" whose A1C climbs anyway once perimenopause hits.
• 04:15 — What Type 2 Diabetes Actually Is Insulin resistance, beta-cell decline, and why genetics account for 40–80% of risk.
• 05:31 — Hormones, Sleep, and PMOS Estrogen as an insulin sensitizer, cortisol and chronic stress, the impact of poor sleep, and PMOS (formerly PCOS) as a major independent risk factor.
• 08:52 — Type 1 vs. Type 2 Clarifier A quick, important distinction — type 1 diabetes is autoimmune and not the topic of this episode.
• 09:15 — CGMs and the "I Can Feel It" Myth Why 64% of patients believe they can feel high blood sugar — and the story of using a CGM to show her dad he couldn't.
• 12:48 — Insulin Fear and Complications Why so many patients believe insulin causes kidney damage, blindness, or amputations — and what actually causes those complications.
• 15:07 — Diet Myths and Shame Vegetarian diets, "only sugar counts," and how internalized shame changes patient behavior.
• 17:32 — Remission, Not Reversal The real data on remission rates over time, and why relapse is disease progression, not failure.
• 19:59 — What Patients Deserve A call for full access to treatment — metformin, GLP-1s, SGLT2 inhibitors, insulin — without having to "earn" it first.
• 22:38 — Menopause and the Diabetes Care Gap Why standard diabetes care ignores perimenopause and menopause, and what should be asked instead.
• 23:48 — Key Takeaways and Share A recap and an invitation to pass this along to anyone who's been made to feel like their diabetes is their fault.

Resources & Mentions:

• Continuous glucose monitors (CGMs) as standard-of-care discussion
• PMOS (formerly known as PCOS)
• Type 2 diabetes remission criteria (A1C <6.5% for 3+ months without medication)

Disclaimer: This podcast is for educational purposes only and is not personalized medical advice. Please discuss anything you hear here with your own healthcare team.

Thanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question.

Getting diagnosed with Hashimoto's can feel overwhelming, especially after spending five minutes online. Suddenly you're told to eliminate gluten, avoid broccoli, stop eating soy, buy expensive supplements, and ask your doctor for desiccated thyroid. But how much of that advice is actually supported by evidence?

In Part 2 of the Thyroid Myth Busting series, endocrinologist Dr. Komal Patil-Sisodia separates fact from fiction using current medical research.

You'll learn:

•  Why cruciferous vegetables are not harming your thyroid 
•  When soy actually matters (hint: it's about medication timing) 
•  Who should—and shouldn't—consider a gluten-free diet 
•  Why iodine supplements can actually worsen thyroid disease 
•  Which thyroid supplements have evidence (and which don't) 
•  The truth about desiccated thyroid versus levothyroxine 

If you've ever felt overwhelmed by thyroid advice on social media, this episode is your evidence-based guide.

Timestamps

00:00 Welcome to Clearly Hormonal

01:03 Why thyroid wellness advice can become overwhelming

02:04 Cruciferous vegetables, iodine, and what actually affects thyroid function

05:03 Soy consumption and levothyroxine timing

06:16 Hashimoto's, gluten, and when celiac testing matters

09:35 The dangers of iodine supplements and seaweed products

13:08 Fact-checking popular thyroid supplements:

•  Ashwagandha 
•  Vitamin B12 
•  Low-dose naltrexone (LDN) 
•  Selenium 

17:05 Desiccated thyroid vs levothyroxine: What the evidence says

23:05 Key takeaways and what's next

Resources & Links:

• Catch up on Part 1 (testing myths, TSH, subclinical hypothyroidism)
• Follow @drpatilsisodia on Instagram and TikTok

Disclaimer: This podcast is for education, not personalized medical advice. Talk to your own healthcare team about what's right for you.

Thanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question.

One in four women will have some degree of thyroid dysfunction after menopause — so it's not unreasonable to test it. But Dr. Komal Patil-Sisodia says the real problem isn't whether we test, it's what we do (or don't do) after the results come back "normal." In this episode, she breaks down the most common thyroid myths she hears in clinic: that fatigue and weight gain automatically mean thyroid disease, that everyone needs a full thyroid panel, and that a slightly elevated TSH always means you need medication. She walks through what TSH actually measures, when free T4 and T3 testing adds value, why antibody testing isn't a default screen, and the real risks of over-treating with levothyroxine. Then she dives into the part almost no one explains: how perimenopause and menopause change the way we interpret thyroid labs, why your TSH reference range shifts with age, and how starting estrogen therapy can change your thyroid medication needs.

Timestamps

• 00:00 — Welcome to Clearly Hormonal
• 01:03 — Is It Really Thyroid?
• 02:27 — Myth 1: Symptoms Automatically Equal Thyroid Disease
• 05:22 — Myth 2: Everyone Needs a Full Thyroid Panel
• 06:04 How TSH Testing Works
• 11:18 — When Extra Testing Actually Matters (pituitary, pregnancy, illness, med changes)
• 18:32 — Thyroid Antibodies: What They Are and When to Check Them
• 19:45 — Myth 3: Subclinical Hypothyroidism Always Needs Treatment
• 23:07 — The Real Risks of Overtreatment (and What the Evidence Shows)
• 26:56 — The Menopause–Thyroid Overlap No One Explains
• 30:51 — How Estrogen Therapy Changes Your Thyroid Labs
• 33:37 — Questions to Ask Your Doctor
• 35:21 — Next Episode Preview & Wrap-Up

Resources & Studies Mentioned

• 2017 TRUST Trial (New England Journal of Medicine) — levothyroxine vs. placebo in adults 65+
• 2025 Annals of Internal Medicine analysis of NHANES data on age/sex/race-specific TSH ranges
• 2026 Hong Kong population study on age- and sex-specific TSH reference ranges
• Korean cohort study of 50,000+ women on thyroid dysfunction across the menopause transition
• JAMA study on successful levothyroxine discontinuation in older adults on low-dose therapy

Connect

• Instagram & TikTok: @drpatilsisodia
• Podcast: Clearly Hormonal
• Practice: eastsidemm.com
• If this episode resonated, share it with a woman in your life who’s been searching for answers. Leave a review so more women can find this podcast.

Disclaimer: This podcast is for educational purposes only and is not a substitute for personalized medical advice. Please discuss your own labs and symptoms with your healthcare team.

Thanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question.

Picture three women. One is spitting into four little tubes throughout the day, mailing them off to a lab, hoping to finally get answers about her "adrenal fatigue." Another has been on a steroid inhaler for years, or just got a cortisone shot in her knee, and has never once had her adrenal glands checked — even though statistically, she has roughly a coin-flip's odds of an abnormal result if anyone bothered to look. And a third, in her late forties, is being told her exhaustion and brain fog are adrenal fatigue, when what she actually needs is a conversation about perimenopause.

Same hormone. Same small gland sitting on top of each kidney. Three completely different ways we get this wrong — and in this episode, Dr. Patil-Sisodia untangles all three.

She starts with the myth: why multi-sample "adrenal fatigue" saliva and urine kits run on real, legitimate lab technology in service of a diagnosis that doesn't medically exist — and why that combination is exactly what makes them so convincing. Then comes the plot twist she didn't expect to be making: that same multi-sample saliva format is actually a gold-standard tool, just for something else entirely — screening for Cushing's syndrome, when cortisol runs too high instead of too low. From there, she walks through the tests that genuinely work for Cushing's, the pseudo-Cushing's patterns (depression, alcohol use, obesity, PCOS/PMOS, illness, and more) that can mimic it on paper, and the condition she says gets missed more than any other: steroid-related adrenal insufficiency, which affects about half of long-term steroid users — inhalers, creams, sprays, and injections included — while fewer than 1% are ever tested for it.

The episode closes on something close to home for this show's listeners: how easily perimenopause gets relabeled as adrenal fatigue, what that mislabeling actually costs women, and three simple questions you can run any cortisol test through before you trust it.

Time Stamps:

[00:00]  Medicine Gets Cortisol Wrong — the three-part setup: wrong tests, wrong people, and the people who need testing but never get it.

[01:07]  Adrenal Fatigue Myth — why multi-sample saliva/urine kits use real lab technology to chase a diagnosis with no recognized normal range.

[03:08]  Real Use for Saliva — the plot twist: late-night saliva testing is legitimate gold-standard science, just for a different question.

[06:19]  Cushing Syndrome Basics — the three tests that actually work: late-night saliva, 24-hour urine cortisol, and overnight dexamethasone suppression.

[07:34]  Pseudo Cushing Pitfalls — how depression, heavy alcohol use, obesity, poorly controlled diabetes, PCOS/PMOS, illness, pain, eating disorders, and intense exercise can mimic Cushing's without being it.

[09:19]  Steroid Induced Adrenal Suppression — the condition affecting roughly half of long-term steroid users (inhalers, creams, sprays, injections, possibly Depo-Provera) while under 1% get tested.

[12:57]  Menopause Misdiagnosed — why perimenopause symptoms get scooped up under the adrenal fatigue umbrella, and what the research does and doesn't show.

[17:06]  Testing Adrenal Insufficiency — the real diagnostic pathway: tapering first, the 8–9 a.m. blood draw, and how to read the result range.

[18:55]  Cosyntropin Test Myths — the standard 250-microgram test versus the unvalidated low-dose version some sources still promote.

[21:06]  Recovery and Reassurance — why an abnormal cortisol number is far more common than a true adrenal crisis, and why recovery can take months to over a year.

[22:21]  Three Questions for Testing — what to ask before trusting any cortisol test: proven diagnosis, meaningful timing, gold-standard validation.

[24:19]  Final Takeaways and Outro.

Key Takeaways

• "Adrenal fatigue" and "chronic stress" are not recognized medical diagnoses — there is no validated normal range for the multi-sample panels marketed to diagnose them.
• The same multi-sample saliva testing format is legitimate gold-standard science — when it's used correctly, at the right time of night, repeated 2–3 nights, to screen for Cushing's syndrome.
• About half of people on long-term steroids (any form — pills, inhalers, creams, sprays, injections) have some degree of adrenal insufficiency. Fewer than 1% are ever tested.
• Perimenopause symptoms (fatigue, brain fog, anxiety, low libido) overlap heavily with the symptoms marketed as "adrenal fatigue" — and that overlap can delay real menopause care.
• Before trusting a cortisol test: ask what it's proven to diagnose, whether the timing matches the question, and whether it's been validated against the gold standard.

Resources & Links

• Follow Dr. Patil-Sisodia: @drpatilsisodia on Instagram and TikTok
• Send fan mail / episode questions via Buzzsprout
• Catch up on the related myth-busting episode referenced in this one (adrenal fatigue supplements)

Thanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question.

“My adrenals are shot.” If you’ve said some version of that sentence this year, Dr. Komal Patil-Sisodia believes that you feel terrible—she just wants you to know that adrenal fatigue isn’t a real diagnosis, a lab value, or something your adrenal glands can actually do. In this myth-busting episode, she takes on six widely held beliefs about the adrenal glands: from the supplement industry built around a condition with no validated test, to when an adrenal tumor actually needs surgery, to who really needs Cushing syndrome screening, to how peri-operative steroid dosing has changed. She closes with the myth she considers most dangerous—that real adrenal insufficiency is easy to spot—and explains why it’s so often missed for years, sometimes until a life-threatening adrenal crisis forces the diagnosis.

Timestamps
00:00:  Welcome to Clearly Hormonal

01:03:  Setting up the adrenal fatigue myth

02:17:  Myth #1: “Adrenal fatigue” isn’t a real diagnosis

04:47:  Myth #2: Are adrenal support supplements safe and effective?

06:18:  Myth #3: Does every adrenal tumor need surgery?

07:57:  Myth #4: Should everyone with obesity or diabetes be screened for Cushing syndrome?

11:00:  Myth #5: Does everyone on chronic steroids need stress-dose steroids for procedures?

12:38:  Myth #6: Is adrenal insufficiency easy to diagnose clinically?

15:58:  Recap and what’s coming next

Thanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question.

Dr. Komal Patil-Sisodia records live from her hotel room on the final night of the ADA 86th Annual Scientific Sessions in New Orleans — still processing what she witnessed earlier that week. The NIH director didn't show up to his own keynote. A substitute speaker framed diabetes research under the MAHA agenda. And five physicians were escorted out of the conference by security for handing out a peer-reviewed article published in the ADA's own journal.

This episode is her unfiltered account of what happened, what the science actually says, and why none of us — patients, clinicians, or researchers — can afford to let it quietly recede.

In this episode:

• What the Kahn et al. Diabetes Care editorial actually argues
• Why an 89% drop in NIH funding notices is more alarming than it sounds
• How a new policy is draining the research pipeline without a single congressional vote
• The landmark diabetes trials — DPP, DCCT, TrialNet — that exist because of the infrastructure now being gutted
• A frank assessment of the ADA's official statement
• Why diverse, long-horizon NIH research is existential for underserved populations
• Concrete actions for patients, clinicians, researchers, and the community

Timestamps:

00:00 Welcome to Clearly Hormonal
01:03 Why This Episode Now
01:38 My Diabetes Roots
02:32 Keynote Cancellation Shock
03:46 Editorial Handout Incident
04:59 Inside the Kahn Editorial
06:13 Funding Collapse Explained
07:57 Oversight Councils Undermined
09:02 Policy Loophole Chokes Grants
10:24 Why NIH Research Matters
11:40 Why I Stayed
13:44 What the Keynote Said
15:35 The Core Contradiction
17:49 ADA Statement Breakdown
21:22 Who Gets Hurt Most
23:55 What We Can Do Next
25:56 Closing and Resources

Resources mentioned:

• Kahn et al. Diabetes Care editorial (2026)
• ADA contact and advocacy tools
• Congressional representative lookup
• House of Representatives lookup
• STAT News coverage of the conference

Find Dr. Patil-Sisodia:

• Instagram & TikTok: @drpatilsisodia
• Eastside Menopause & Metabolism

Clearly Hormonal is for educational purposes only and does not constitute personalized medical advice. Please discuss your individual health concerns with your own healthcare provider.

Thanks for listening. Find more info about Clearly Hormonal on the website or Instagram.

📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question.

On May 12, 2026, The Lancet published the results of a 14-year global effort: Polycystic Ovarian Syndrome (PCOS) has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). For over 170 million women worldwide — most of whom have never received a correct diagnosis — this is not just a nomenclature update. It is a reckoning.

In this episode, Dr. Komal Patil-Sisodia breaks down what changed, what didn’t, and why the new name carries profound clinical implications across every hormonal era: adolescence, the reproductive years, perimenopause, and menopause and beyond. She connects the renaming to the 2026 ACC/AHA dyslipidemia guidelines, the 70% undiagnosis rate, and the lifelong metabolic consequences that the old name made invisible.

If you’ve ever been handed a birth control pill without a workup, told your symptoms were stress, or felt dismissed in a clinical setting — this episode is for you.

Timestamps

00:00  Welcome to Clearly Hormonal  —  Dr. Patil-Sisodia introduces the podcast and her clinical background across endocrinology, internal medicine, obesity medicine, and menopause care.

01:08  PCOS Gets Renamed  —  The official May 12, 2026 announcement in The Lancet: PCOS is now Polyendocrine Metabolic Ovarian Syndrome (PMOS). Why one letter — C to M — changes everything.

02:38  Why the Old Name Hurt  —  The 14-year global process led by Professor Helena Teede involving 56 organizations and 22,000+ survey responses. How the word “polycystic” misdirected care for generations and contributed to delayed diagnosis, stigma, and fragmented treatment.

04:32  Breaking Down PMOS  —  Word-by-word analysis: Polyendocrine (system-level hormonal disruption), Metabolic (insulin resistance, cardiovascular risk as core features, not side effects), Ovarian dysfunction (still present, but no longer the whole story).

05:48  What Did Not Change  —  The Rotterdam diagnostic criteria remain intact. If you were diagnosed with PCOS, you have PMOS. Your clinical picture is valid. What changed is the language — and what that language demands of clinicians.

07:19  Adolescence — The Era of Missed Beginnings  —  How PMOS manifests in teenage girls, why it gets dismissed as normal puberty, and what’s at stake when early insulin resistance goes untreated. The window to act — and how the new name changes what clinicians look for.

10:37  Reproductive Years — The Era of Diagnosis and Distraction  —  Why PMOS is most often diagnosed in fertility contexts, and why that misses the metabolic picture. The connection to gestational diabetes, preeclampsia risk, and the 2026 ACC/AHA dyslipidemia guidelines.

13:58  Perimenopause — The Era That Intensifies  —  How declining ovarian function accelerates metabolic dysfunction in women with PMOS. Why symptoms quiet in the 30s and return louder in the 40s. The urgent research questions the new name demands.

17:16  Menopause and Beyond — The Era the Name Change Protects  —  Why post-menopausal women with PCOS/PMOS history face the highest cardiovascular risk of their lives — and why no one is connecting the dots. Lp(a), ApoB, and what to ask your clinician today.

19:09  What the Name Actually Changes  —  A clinical summary: how each word in PMOS shifts the posture of care at every hormonal era. One name. Four eras. A completely different approach.

20:56  Takeaways and Call to Action  —  What to do if you have a PMOS diagnosis, what to ask your clinician if you’re post-menopausal, and a message to clinicians: the name changed. Now the care has to change with it.

What We Cover

• The official renaming of PCOS to PMOS (Polyendocrine Metabolic Ovarian Syndrome) in The Lancet, May 2026
• Why the word “polycystic” was scientifically inaccurate and caused measurable clinical harm
• What each word in PMOS actually means clinically
• Why 70% of people with this condition remain undiagnosed — and how framing drives that number
• Era-by-era breakdown: adolescence, reproductive years, perimenopause, menopause and beyond
• The 2026 ACC/AHA dyslipidemia guideline connection: PMOS as a cardiovascular risk enhancer
• Lp(a) and ApoB: why Class 1 universal screening now matters for your PMOS history
• What to ask your clinician at every stage

Resources Mentioned

• The Lancet PMOS Renaming Paper — May 12, 2026
• Professor Helena Teede, Monash University — lead researcher
• Rotterdam Diagnostic Criteria for PMOS
• 2026 ACC/AHA Dyslipidemia Guideline (PREVENT equations, Lp(a) universal screening, ApoB targets)
• The Endocrine Society — one of 56 organizations in the renaming process

Connect

• Instagram: @drpatilsisodia
• Podcast: Clearly Hormonal
• Practice: eastsidemm.com
• If this episode resonated, share it with a woman in your life who’s been searching for answers. Leave a review so more women can find this podcast.

Thanks for listening. Find more info about Clearly Hormonal on the website or Instagram.